| valsartan / Generic mfg. |
2004-003235-31: Effect of pravastatin or fluvastatin and add-on valsartan on inflammatory markers and peripheral endothelial function in patients with acute coronary syndrome |
|
|
| Ongoing | 4 | 80 | Europe | Lescol, Diovan, PRAVASTATIN "RATIOPHARM", Tablet, Lescol, Diovan, PRAVASTATIN "RATIOPHARM" | Div. of Cardiology, Innsbruck Medical University | Acute coronary syndrome; patients with NSTEMI | | | | |
ChiCTR-TRC-10001071: The Effect of Amlodipine and Valsartan in Hypertensive Renal Post-transplant Patients |
|
|
| Completed | 4 | 150 | | amlodipine(Norvase, 5mg/tablet) + metoprolol(Betaloc,12.5mg/tablet) ;valsartan(Diovan, 80mg/tablet) +metoprolol(Betaloc,12.5mg/tablet) | the Third Xiangya Hospital of Central South University; Hunan Science and Technology Bureau, Science and Technology Program of Hunan (2006SK2003) | Post-transplant hypertension | | | | |
ChiCTR-TRC-12004443: The Infect of Olmesartan on Atrial Fibrillation Load in Patients with Sick Sinus Syndrome |
|
|
| Completed | 4 | 120 | | Valsartan ;Placebo | Nanjing First Hospital Department Of Cardiology; Nanjing First Hospital Department Of Cardiology, self-raised | Sick Sinus Syndrome | | | | |
ChiCTR-IPR-14005368: Prospective trial of leflunomide in the treatment of immunoglobulin A nephropathy |
|
|
| Not yet recruiting | 4 | 60 | | leflunomide 20mg/d ;Valsartan 80mg/d | West China Hospital of Sichuan University; Level of the institution：, Funding Opportunity | immunoglobulin A nephropathy | | | | |
ChiCTR-TRC-12002642: Upstream Therapeutic Strategies of Valsartan and Fluvastatin on Hypertension Patients with Non-chronic Atrial Fibrillation |
|
|
| Completed | 4 | 2000 | | Valsartan ;fluvastatin & CCB ;valsartan & fluvastatin ;CCB | The second hospital of Tianjin Medical University; Level of the institution：, Unit self-finance, financial appropriation | Hypertension Patients with Atrial Fibrillation | | | | |
2004-001270-77: Estudio piloto para evaluar la eficacia y seguridad de Valsartán para el control de la progresión de la insuficiencia renal y la morbimortalidad cardiovascular en pacientes con trasplante renal funcionante con proteinuria e insuficiencia renal leve o moderada. |
|
|
| Ongoing | 4 | 178 | Europe | Diovan, HIPOTENSORES, DIURETICOS, VASODILATADORES PERIFÉRICOS, BETABLOQUEANTES, CALCIO ANTAGONISTAS, C02, C03, C04, C07, C08, DIOVAN, DIOVAN | Equipo de doctores: Dr. Amado Andrés y Dr. Manuel Praga | Pacientes varones y mujeres de 18 a 70 años con trasplantes renales funcionantes de más de 1 año de evolución y una insuficiencia renal leve o moderada (creatinina sérica > 1,3 mg/dl en mujeres y > 1,5 mg/dl en varones y < 3 mg/dl en ambos casos) y proteinuria (>0,5 g/24 h y < 3,5 g/24 h). | | | | |
2006-000523-34: Intensiv ikke-sympatikus aktiverende vasodilaterende behandling hos patienter med mikrovaskulær angina pectoris |
|
|
| Ongoing | 4 | 115 | Europe | Zanidip, Diovan, Doxazosin \"Stada\", Moxonidin \"Alpharma\", Visken, Sparkal, Selo-Zok, Myonil Retard, Isodur, Centyl med kaliumchlorid, Angicor, Zanidip, Diovan, Doxazosin \"Stada\", Moxonidin \"Alpharma\", Visken, Sparkal, Selo-Zok, Myonil Retard, Isodur, Centyl med kaliumchlorid, Angicor | Århus Sygehus | Patienter med hypertension og angina pectoris og ingen signifikante stenoser ved koronararteriografi (KAG). | | | | |
2006-003473-27: Wirkung von Telmisartan 80 mg im Vergleich zu Valsartan 160 mg auf die Insulinsensitivität (HOMA) - WITEVA - |
|
|
| Ongoing | 4 | 40 | Europe | Diovan / Kinzal, BAY69-9291, Diovan 80/160 Kinzal 40/80, Diovan 80/160 Kinzal 40/80 | MedQuality Forschung GmbH | Hypertension | | | | |
2006-006719-66: Efficacité d’un traitement par l’association amlodipine et valsartan en monoprise vespérale ou matinale, chez des Patients présentant une HTA Essentielle moyenne à modérée, non contRôlée par amlodipine 5mg en mesure ambulatoire de la pression arTérielle: Etude ExPERT |
|
|
| Ongoing | 4 | 45 | Europe | Tareg, Amlor, Tareg, Amlor, Tareg, Amlor | Novartis Pharma S.A.S. | HTA essentielle | | | | |
2008-000804-10: Valsartan 160 mg and hydrochlorothiazide 25 mg in subject suffering from arterial hypertension stage 1 or high normal with organ damage |
|
|
| Ongoing | 4 | 20 | Europe | CORIXIL, CORIXIL | UNIVERSITA, DEGLI STUDI DI NAPOLI FEDERICO II | Arterial Hypertension with organ damage | | | | |
2007-007482-21: Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria with ACE Inhibitors and ARBS in Patients with Fabry Diseaswe Who Are receiving Farazyme : Tha Farazyme + Arbs + ACE inhibitors Treatments (FAACET) Study: The FAACET Study |
|
|
| Ongoing | 4 | | Europe | perdix, ZESTORIC, innozide, lisinopril, zestril, coversyl, coversyl PLUS, Accupro, Accuretic, lopace, triapin& triapin Mite, rampril, tritace, gopten, carace, Staril, acepril, CAPOZIDE, AMIAS, TEVETON, aprovel, 0lmetec, micardis, Co Diovan, perdix, Zestoretic 10,20, INNOZIDE, lisinopril, zestril, coversyl, coversyl PLUS, Accupro, Accuretic, lopace, triapin, RAMPRIL, TRITACE, GOPTEN, carace, Staril, Acepril, CAPOZIDE, CAPOTEN, AMIAS, TEVETEN, aprovel, olmetec, micardis, Co Diovan, perdix, Zestoretic 10,20, INNOZIDE, lisinopril, zestril, coversyl, coversyl PLUS, Accupro, Accuretic, lopace, triapin, RAMPRIL, TRITACE, GOPTEN, carace, Staril, Acepril, CAPOZIDE, CAPOTEN, AMIAS, TEVETEN, aprovel, olmetec, micardis, Co Diovan | Salford Royal NHS Foundation Trust | Fabry disease with proteinuria. | | | | |
2016-002897-10: Determination of drug amounts in the duodenum with the help of a catheter Bepaling van de hoeveelheid geneesmiddelen in de darm met behulp van een katheter. |
|
|
| Ongoing | 4 | 5 | Europe | Perdolan, Clamoxyl, Diovane, Syrup, Tablet, Perdolan, Clamoxyl, Diovane | KU Leuven - Drug Delivery and Disposition, KU Leuven | Healthy human volunteers, investigation of free drug concentrations in the duodenum Gezonde vrijwilligers, onderzoek naar vrije concentraties in de darm, Healthy human volunteers, investigation of free drug concentrations in the duodenum Gezonde vrijwilligers, onderzoek naar vrije concentraties in de darm, Body processes [G] - Digestive System and Oral Physiological Phenomena [G10] | | | | |
2017-000213-23: Dual treatment for patients with chronic kidney disease, high blood pressure and diabetes. Combinatiebehandeling voor chronische nierschade bij hoge bloeddruk en diabetes. |
|
|
| Ongoing | 4 | 31 | Europe | Tablet, Entresto, Valsartan | | Chronic kidney disease with concurrent hypertension and diabetes. Chronische nierinsufficientie bij hypertensie en diabetes mellitus., Chonic kidney disease with concurrent high blood pressure and diabetes. Chronische nierschade bij hoge bloeddruk en suikerziekte., Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | | | | |
2017-003672-31: Fixed-dose combination of rosuvastatin and valsartan for dual target achievement in patients with hypertension and hyperlipidaemia (UNIFY) |
|
|
| Not yet recruiting | 4 | 280 | Europe | Ravalsyo, Film-coated tablet, Ravalsyo® | KRKA, d.d., Novo mesto, KRKA d.d., Novo mesto | Patients with mild to moderate essential arterial hypertension AND primary hypercholesterolemia or mixed dyslipidaemia (LDL-c < 4.9 mmol/L or <189.5 mg/dl) with moderate, high or very high risk for cardiovascular event., Patients with mild to moderate essential arterial hypertension AND primary hypercholesterolemia or mixed dyslipidaemia with moderate, high or very high risk for cardiovascular event., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2018-003936-62: VALSARTAN TREATMENT COMPARED IN RENAL TRANSPLANT RECIPIENTS WITH SIGNS OF POST TRANSPLANT GLOMERULOPATHY TRATAMIENTO CON VALSARTÁN EN PACIENTES TRASPLANTADOS RENALES CON SIGNOS DE GLOMERULOPATÍA POST TRASPLANTE |
|
|
| Not yet recruiting | 4 | 180 | Europe | Tablet | HOSPITAL UNIVERSITARI DE BELLVITGE-IDIBELL, INSTITUTO DE SALUD CARLOS III | POST TRANSPLANT RENAL GLOMERULOPATHY GLOMERULOPATÍA RENAL POST TRASPLANTE, CHRONIC RENAL IMPAIRMENT AFTER RENAL TRANSPLANTATION DAÑO RENAL CRÓNICO TRAS EL TRASPLANTE RENAL, Body processes [G] - Immune system processes [G12] | | | | |
ChiCTR1800019346: Evaluation of the bioequivalence of Valsartan Capsules 80 mg on fasting and fed conditions |
|
|
| Recruiting | 4 | 84 | | 1 capsule was dosed in each cycle/each subject, total 3 cycles. ;1 capsule was dosed in each cycle/each subject, total 3 cycles. | First Hospital of Jilin University; First Hospital of Jilin University, China Resources Saike Pharmaceutical Co.,Ltd. | mild to moderate essential hypertension | | | | |
ChiCTR1800015649: New active element (rhBNP) sequential sand kubah song/valsartan (LCZ696) in the treatment of acute heart failure study |
|
|
| Not yet recruiting | 4 | 300 | | base treament ;rhBNP combine base treatment ;rhBNP combine LCZ696 | Tianjin Union Medical Center; Tianjin Union Medical Center, self-raised | acute heart failure | | | | |
ChiCTR1900025506: Clinical observation of Sacrubitril/Valsartan in the treatment of heart failure |
|
|
| Recruiting | 4 | 300 | | use Sacrubitril /valsartan ;use ACEI | China-Japan Union Hospital of Jilin Universuty; China-Japan Union Hospital of Jilin University, Jilin Province Key Laboratory of Cardiovascular Disease Genetic Diagnosis | heart failure | | | | |
2021-001327-41: Withdrawal of pharmacological treatment in patients responding to cardiac resynchronization therapy: Open and randomized study Retirada de tratamiento farmacologico en pacientes respondedores a terapia de resincronización cardiaca: Estudio abierto y aleatorizado |
|
|
| Ongoing | 4 | 60 | Europe | furosemide, bisoprolol, Coated tablet, Furosemide, Bisoprolol, Eplerenone, Valsartan | Fundación para la formación e investigación sanitarias de la Región de Murcia, ISCarlos III | Heart failure Insuficiencia cardiaca, Heart failure Insuficiencia cardiaca, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR1900024752: Clinical Study for Intensive Glucose Control Combined With Double RAS Inhibitory Therapy for Type 2 Diabetic Nephropathy |
|
|
| Recruiting | 4 | 120 | | Intensive insulin therapy+Valsartan capsule 80mg + perindopril tert-butylamine tablets 4mg 1/day ;Intensive insulin therapy+Valsartan capsule160mg 1/day ;Intensive insulin therapy+perindopril tert-butylamine tablets 8mg 1/day | Nephrology Division, the First Hospital Affiliated to Army Medical University; The First Hospital Affiliated to Army Medical University, Chongqing Science and Health Joint Medical Research Project | Type 2 Diabetic Nephropathy | | | | |
ChiCTR1900028468: Efficacy and safety of sacurabatril valsartan in patients with heart failure and renal insufficiency |
|
|
| Recruiting | 4 | 120 | | Treatment with ARNI ;Treatment with Valsartan | The First Central Hospital of Tianjin; First Central Hospital of Tianjin, Self-raised | Chronic Heart Failure and Chronic kidney disease（CKD）stage 1-3 | | | | |
ChiCTR2100043953: A study of Sacubatril/valsartan in improving prognosis of uremia patients with heart failure on peritoneal dialysis |
|
|
| Recruiting | 4 | 60 | | Sacubatril/valsartan | Department of Nephrology, General Hospital of Ningxia Medical University; Department of Nephrology, General Hospital of Ningxia Medical University, Funding for other scientific research projects | Uremia peritoneal dialysis with heart failure | | | | |
MRA-ACE, NCT03502031: Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy |
|
|
| Recruiting | 4 | 72 | US | Renin-Angiotensin (RAAS) alone, Lispril, Enalapril, Perindopril, Losarta, Valsar etc.,, Renin-Angiotensin (RAAS) blockers in combination with Spironolactone, Lisinopril, Enalapril, Perindopril, Losartan, Valsartan, or Spironolactone | James A. Tumlin, MD, Nelson Kopyt, MD | Renal Insufficiency, Chronic, Diabetic Nephropathy Type 2 | 10/22 | 10/24 | | |
ChiCTR2200062762: Clinical study of valsartan reducing the incidence of grade 2 or higher radiation pneumonitis after thoracic radiotherapy |
|
|
| Not yet recruiting | 4 | 60 | | valsartan | Ji'nan Central Hospital; Ji'nan Central Hospital, Scientific research funding of Oncolgy department ，Jinan Central Hospital | lung cancer | | | | |
ChiCTR2000034557: The effect of Chinese herbal medicine Shugan Wendan Decoction for the treatment of H-type essential hypertension: a ranodmized controlled trial. |
|
|
| Not yet recruiting | 4 | 90 | | Valsartan (80mg, po, q.d.) ;Valsartan capsules, 80mg, po q.d.+ Shugan Wendan soup, po, q.d. | Guangdong Provincial Hospital of Traditional Chinese Medicine; Guangdong Provincial Hospital of traditional Chinese Medicine, Self-raised | H-type essential hypertension | | | | |
| Not yet recruiting | 4 | 68 | NA | Valsartan, Novartis | Fifth Affiliated Hospital, Sun Yat-Sen University, Third Affiliated Hospital, Sun Yat-Sen University | Hypertension;Nephropathy | 06/23 | 12/23 | | |
NCT04769778: Renin Angiotensin System Blockade in Renal Transplant Patients With Presence of PECs in Urine |
|
|
| Recruiting | 4 | 180 | Europe | Valsartan 80Mg Oral Tablet | Josep M Cruzado | Chronic Kidney Allograft Nephropathy | 06/23 | 06/23 | | |
NCT05269615: Exercise-induced Erythropoiesis: the Mechanistic of Angiotensin II |
|
|
| Recruiting | 4 | 80 | RoW | Valsartan 80 mg, Placebo | The University of Hong Kong | Exercise Physiology | 09/24 | 09/24 | | |
NCT05095922: Effect of HMP on Diabetic Microangiopaemia in T2DM |
|
|
| Completed | 4 | 40 | RoW | Heart-Protecting Musk Pill, Heart-Protecting Musk Pill，National Medicine Permission Number Z31020068，86900674000453, Valsartan Capsules, Valsartan Capsules，National Medicine Permission Number H20040217，86900100000095, Calcium Dobesilate Capsules, Doxium，H20140641 | Affiliated Hospital of Nantong University | Diabetes Mellitus, Type 2, Diabetic Angiopathies | 05/24 | 05/24 | | |
ChiCTR2000035327: Comparison of ARNI and ARB in the treatment of elderly patients with acute decompensated ejection fraction preserved heart failure |
|
|
| Not yet recruiting | 4 | 40 | | ARNI 24/26mg bid;49/51mg bid;97/103mg bid ;ARB 40mg bid;80mg bid;160mg bid | Shanghai General Hospital; Shanghai General Hospital, self-raised | heart failure | | | | |
NCT03938389: The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans |
|
|
| Active, not recruiting | 4 | 90 | US | Sacubitril-Valsartan Tab 97-103 MG, Entresto, Valsartan 160mg, Diovan, Placebo Oral Tablet | Ohio State University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | PreDiabetes, Impaired Glucose Tolerance, Obesity, Blood Pressure | 02/24 | 06/25 | | |
| Recruiting | 4 | 130 | Europe | Perindopril, Valsartan | Academisch Ziekenhuis Maastricht, ZonMw: The Netherlands Organisation for Health Research and Development | Heart Failure, Diastolic Dysfunction | 03/26 | 03/26 | | |
NCT03738878: Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1 |
|
|
| Active, not recruiting | 4 | 32 | US | Valsartan, LCZ696, Entresto, Bradykinin, Substance P, BNP, Nesiritide, Sitagliptin, Januvia | Vanderbilt University Medical Center | Hypertension | 07/25 | 12/25 | | |
ChiCTR2300068678: A single-center, randomized, prospective clinical study of Azisartan versus valsartan in the treatment of post-infarction ventricular remodeling in patients with diabetes after STEMI |
|
|
| Not yet recruiting | 4 | 240 | | Azisartan 20-40mg orally ;Valsartan 80-160mg orally | The People’s Hospital of Liaoning Province; The People’s Hospital of Liaoning Province, Supported by Xinxin Cardiovascular Health Foundation | Acute myocardial infarction | | | | |
ChiCTR2300076082: A single-center randomized crossover controlled trial to evaluate the efficacy and safety of azisartan in the treatment of proteinuria and renal function in non-dialytic hypertensive patients with IgA nephropathy |
|
|
| Not yet recruiting | 4 | 302 | | The first 12 weeks after taking azilsartan to valsartan; After taking valsartan in the first 12 weeks, it was changed to azilsartan. | Chinese Cardiovascular Association-HX Fund; Department of Nephrology, The Third Affiliated hospital of Southern Medical university, Guangzhou, China., Chinese Cardiovascular Association-HX Fund | IgA nephropathy | | | | |
NCT04263922: Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3 |
|
|
| Recruiting | 4 | 466 | RoW | Huaiqihuang granules, B12000050755, Valsartan capsule, H20030638 | The First Affiliated Hospital of Dalian Medical University, Huazhong University of Science and Technology, LinkDoc Technology (Beijing) Co. Ltd. | Renal Insufficiency, Chronic | 10/25 | 03/26 | | |
NCT02817360: NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients |
|
|
| Recruiting | 4 | 2400 | Europe, RoW | RAS-antagonist and beta-blocker up-to maximal dosages, Enalapril 40mg/d, Ramipril 10mg/d, Lisinopril 40mg/d, Cilazapril 5mg/d, Perindopril 8mg/d, Captopril 150mg/d, Spirapril 24mg/d, Quinapril 40mg/d, Trandolapril 4mg/d, Zofenopril 60mg/d, Fosinopril 40mg/d, Candesartan 32mg/d, Valsartan 320mg/d, Irbesartan 300mg/d, Losartan 150mg/d, Eprosartan 800mg/d, Bisoprolol 10mg/d, Metoprololsuccinat 200mg/d, Carvedilol 50mg/d (100mg/d if weight is > 85kg), Nebivolol 10mg/d, RAS-antagonist and beta-blocker none or at stable dose | Martin Huelsmann | Heart Diseases, Diabetes Mellitus, Type 2 | 12/25 | 12/26 | | |
NCT06035978: Determination of Drug Levels for Pharmacotherapy of Heart Failure |
|
|
| Not yet recruiting | 4 | 100 | RoW | Nebivolol, Nebilet, anatomical-therapeutic-chemical code (ATC) C07AB12, Valsartan and Sacubitril, Entresto, ATC C09DX04, Carvedilol, Dilatrend, ATC C07AG02, Bisoprolol, Concor, ATC C07AB07, Metoprolol, Betaloc ZOK, ATC C07AB02, Spironolactone, Verospiron, ATC C03DA01 | University Hospital Ostrava | Cardiovascular Diseases, Heart Failure With Reduced Ejection Fraction | 04/26 | 04/26 | | |
2015-000239-34: A clinical study to investigate the use of commonly used heart failure medicines in the prevention of heart related illnesses in patients with diabetes mellitus but without heart disease. |
|
|
| Ongoing | 3/4 | 2400 | Europe, RoW | Enalapril maleate, Ramipril, Lisinopril dihydrate, Perindopril arginine, Perindopril erbumine, Perindopril tert-butylamine, Captopril, Quinapril hydrochloride, Trandolapril, Fosinopril sodium, Candesartan cilextil, Valsartan, Irbesartan, Losartan potassium, Eprosartan mesilate, Bisoprolol fumerate, Carvedilol, Nebivilol hydrochloride, Not applicable, Tablet, , Capsule | Medizinische Universität Wien, Medical University of Vienna, Medizinische Universität Wien, | Type 2 diabetes mellitus, Type 2 diabetes, Diseases [C] - Hormonal diseases [C19] | | | | |
VALUE, NCT06395194: Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension |
|
|
| Completed | 3 | 15313 | NA | Cardiac outcomes on treatment with valsartan, Angiotensin-receptor blocker, Cardiac outcomes on treatment with amlodipine, Calcium-channel blocker | Oslo University Hospital, University of Oslo | Essential Hypertension | 09/03 | 12/03 | | |
2005-004380-32: RANDOMISED, CONTROLLED STUDY WITH A BLINDED END-POINT TO EVALUATE BY MEANS OF 24-HOUR AMBULATORY BLOOD PRESSURE MONITORING THE ANTIHYPERTENSIVE ACTIVITY OF OLMESARTAN 20 MG IN COMPARISON WITH THAT OF VALSARTAN 160 MG, AND THEIR COMBINATION WITH HYDROCHLOROTIAZIDE IN PATIENTS WITH MODERATE ARTERIAL HYPERTENSION WITH ANOTHER CARDIOVASCULAR RISK FACTOR.. |
|
|
| Ongoing | 3 | 187 | Europe | OLMETEC*28CPR RIV 20MG, TAREG*28CPS 160MG, ESIDREX*20CPR 25MG, OLMETEC*28CPR RIV 20MG, TAREG*28CPS 160MG, ESIDREX*20CPR 25MG | UNIVERSITA DEGLI STUDI DI PAVIA | Hypertension | | | | |
2006-002262-19: Angiotensin II receptor blockers in patients with systemic right ventricle. |
|
|
| Ongoing | 3 | 128 | Europe | Diovan, | Novartis Pharma B.V. | Systemic right ventricle due to total transposition of the great arteries or congenitally corrected transposition of the great arteries | | | | |
2006-001812-65: A randomized, double-blind, placebo-controlled, parallelgroup, multicenter study to evaluate the effect of valsartanon proteinuria and glomerular filtration rate in children withChronic Kidney Disease who are receiving a standardizeddose of angiotensin converting enzyme inhibitor therapy |
|
|
| Ongoing | 3 | 9 | Europe | Valsartan, VAL489, Diovan 40 mg film-coated tablet, Diovan 80 mg film-coated tablet, Diovan 40 mg film-coated tablet, Diovan 80 mg film-coated tablet | Novartis Pharma Services AG | Chronic kidney disease is characterized by a progressive decline of glomerularfiltration rate (GFR), which occurs irrespectively of the cause of the renal damage once a critical nephron mass has been lost. | | | | |
2006-006611-68: Valsartan on top of standard therapy as a novel therapeutic strategy to treat cardiac dysfunction in patients with infammatory cardiomyopathies |
|
|
| Ongoing | 3 | 64 | Europe | diovan, Diovan | academic hospital Maastricht | patients suffering from heartfailure and inflammatory cardiomyopthies | | | | |
2008-000628-25: The effectiveness of intensive treatment on sympathetic hyperactivity. A randomized, cross-over trial in patients with chronic kidney disease and hypertension |
|
|
| Ongoing | 3 | 30 | Europe | Valsartan, RVG34472, Diovan, Diovan | UMC Utrecht | Sympathetic nerve system in hypertensive patients with chronic kidney disease | | | | |
ARBs CORONA II, NCT04606563: Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? |
|
|
| Terminated | 3 | 341 | Europe, Canada | Losartan, Cozaar, Valsartan, Diovan, Azilsartan, Edarbi, Candesartan, Atacand, Eprosartan, Teventen, Irbesartan, Avapro, Olmesartan, Olmetec, Telmisartan, Micardis | University of British Columbia, Canadian Institutes of Health Research (CIHR) | Covid19, SARS-CoV Infection | 04/22 | 04/22 | | |
2022-000513-14: Evaluation of the Efficacy of Valsartan in Slowing Down Aortic Root Dilatation in Children and Young Adults with Marfan |
|
|
| Not yet recruiting | 3 | 180 | Europe | Valsartanum 40 mg / Placebo 1, Valsartanum 80 mg / Placebo 2, Coated tablet, Valsacor, Valzek | Medical University of Gdańsk, Medical Research Agency | Marfan SyndromeDiseases related to Marfan syndrome (rare diseases with aneurysms of the thoracic aorta and dissection of the aorta), among others: Loeys-Dietz syndrome, Vascular type of Ehlers-Danlos syndrome, Arterial Tortuosity syndrome, Shprintzen-Goldberg syndrome, Neonatal form of Marfan syndrome, Aneurysms-osteoarthritis syndrome, Multi-system smooth muscle dysfunction syndrome, Familial thoracic aortic aneurysms and aortic dissections, etc., Marfan Syndrome and diseases related to Marfan Syndrome, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
SPH3127-301, NCT05359068: Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension |
|
|
| Completed | 3 | 957 | RoW | SPH3127 tablet, Valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Essential Hypertension | 12/23 | 12/23 | | |
OPTION TREAT, NCT05920005: Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension |
|
|
| Recruiting | 3 | 698 | RoW | candesartan cilexetil + chlorthalidone + amlodipine, Exforge HCT® (valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg) | Hospital Israelita Albert Einstein, Libbs Farmacêutica LTDA | Hypertension | 12/23 | 07/24 | | |
STABILIZE-CKD, NCT05056727 / 2021-001911-96: A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia |
|
|
| Terminated | 3 | 716 | Europe, Canada, Japan, US, RoW | Sodium Zirconium Cyclosilicate (SZC), Lokelma TM, Placebo, Lisinopril, Valsartan, Irbesartan | AstraZeneca | Renal Insufficiency, Chronic, Hyperkalemia | 02/24 | 02/24 | | |
| Recruiting | 3 | 20000 | Europe, Canada, Japan, US, RoW | Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir | UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore | Community-acquired Pneumonia, Influenza, COVID-19 | 02/26 | 02/28 | | |
ARISTOTE, NCT03315832: Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study |
|
|
| Withdrawn | 2/3 | 110 | Europe | Valsartan, Placebo Oral Tablet | University Hospital, Limoges | Aortic Valve Stenosis, Valsartan, Angiotensin Receptor Antagonists, Transcatheter Aortic Valve Replacement, Heart Valve Prosthesis Implantation, Hypertrophy, Left Ventricular | 07/25 | 07/25 | | |
2015-002283-16: An international study of the effect of Valsartan in hypertrophic cardiomyopathy. ET INTERNATIONALT STUDIE VEDRØRENDE EFFEKTEN AF VALSARTAN TIL PATIENTER MED HYPERTROFISK KARDIOMYOPATI |
|
|
| Ongoing | 2 | 150 | Europe | Coated tablet, Diovan 40 mg, Diovan 80 mg, Diovan 160 mg | National Heart, Lung, and Blood Institute / National Institutes of Health, Heart Development and Structural Diseases Branch / Division of Cardiovascular Sciences National Heart, Lung, and Blood I | Hypertrophic cardiomyopathy Hypertrofisk kardiomyopati, Hypertrophic cardiomyopathy Hypertrofisk kardiomyopati, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
PARABLE, NCT02682719: ARNI in Asymptomatic Patients With Elevated Natriuretic Peptide and Elevated Left Atrial Volume Index eLEvation |
|
|
| Recruiting | 2 | 250 | Europe | LCZ696, Valsartan and sacubitril, Entresto, Valsartan, Diovan, Placebo to LCZ696, Placebo to Valsartan | The Heartbeat Trust, Novartis Ireland Ltd | Diastolic Dysfunction | 12/18 | 12/18 | | |
2020-001431-27: Is there a benefit in treating novel corona virus (Sars-CoV2) infections with the established antihypertensive valsartan? Ist eine Behandlung von Infektionen des neuartigen Coronavirus (Sars-CoV2) mit dem bekannten Blutdruckmedikament Valsartan vorteilhaft? |
|
|
| Ongoing | 2 | 300 | Europe | Tablet, , P- Tabletten Weiß 10mm Lichtenstein Tabletten | Klinikum St. Georg gGmbH, Klinikum St. Georg gGmbH | Sars-Cov2 infection Sars-Cov2 Infektion, infection with novel corona Virus (Sars-CoV2) Infektion mit neuartigem Coronavirus (Sars-CoV2), Diseases [C] - Virus Diseases [C02] | | | | |
ChiCTR2000036692: Clinical Study on the Treatment of Foot Cell Injury in Diabetic Nephropathy Patients with Chinese Medicine Xiaoke Decoction |
|
|
| Not yet recruiting | 2 | 40 | | Oral valsartan 80mg/ day ;Oral valsartan 80mg/ day combined with traditional Chinese medicine "Xiaoketang" compound | Shanghai Traditional Chinese Medicine Hospital; Shanghai Traditional Chinese Medicine Hospital, Shanghai Shen Kang hospital development center | Diabetic nephropathy | | | | |
NCT05593575: Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease |
|
|
| Recruiting | 2 | 320 | RoW | SPH3127+SPH3127matching placebo+valsartan matching placebo, SPH3127+valsartan matching placebo, SPH3127 matching placebo+valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Diabetic Kidney Disease | 09/24 | 03/25 | | |
NCT05638880: Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease |
|
|
| Recruiting | 2 | 60 | RoW | Valsartan 80 mg, Empagliflozin 10 MG, Levocetirizine | Mostafa Bahaa, Sahar El-Haggar, Prof Clinical pharmacy Department- Tanta University, Osama Mohamed Hassan Ibrahim , Prof Clinical pharmacy Department- Tanta University, Maryam Ali Ali El Sayed Rizk Clinical pharmacy Department- Tanta University | Diabetic Nephropathies | 12/25 | 10/26 | | |
| Recruiting | 2 | 60 | US | Valsartan 40 mg, Diovan, Placebo | University of Washington, National Heart, Lung, and Blood Institute (NHLBI) | Pulmonary Arterial Hypertension, Right Heart Failure, Right Ventricular Dysfunction, Pulmonary Vascular Disorder | 07/27 | 07/27 | | |
RESILIENCE, NCT03686657: Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients |
|
|
| Not yet recruiting | 1/2 | 115 | US | Metformin, Glucophage, Glucophage XR, Val, Cel and Met XR Low, Diovan, Celebrex, RK-01, Val, Cel and Met XR High | ARKAY Therapeutics, Albany Medical College | Type 2 Diabetes, High Blood Pressure, Arthritis, Obesity | 11/28 | 01/29 | | |
| Recruiting | 1 | 40 | | 1 ;2 ;1 ;2 | Institute of Clinical Pharmacy, Central South University; Synco Limited, Hong Kong, Synco Limited,Hong Kong | Pharmacokinetics and Bioequivalence Study in human | | | | |
NCT04623866: Study on the Treatment of Children With Purpura Nephritis With Huaiqihuang Granules |
|
|
| Not yet recruiting | 1 | 10 | RoW | Huaiqinhuang, Huaiqihuang granules, valsartan, Valsartan capsule | The Children's Hospital of Zhejiang University School of Medicine | Henoch Schönlein Purpura Nephritis | 08/21 | 08/21 | | |
ChiCTR2100048078: Clinical effect and mechanism of Shenan decoction in the treatment of diabetic nephropathy：A Randomized Controlled Clinical trial study Protocol |
|
|
| Not yet recruiting | 1 | 124 | | Shen'an decoction ;Valsartan | Affiliated Hospital of Changchun University of Chinese Medicine; Capital Medical University, This work was supported by the National Key Research and Development Program of China (2018YFC1704100);Research on Academic Viewpoints, Characteristic Diagnosis and Treatment Methods and Experience in | Diabetic Nephropathy | | | | |
| Completed | 1 | 72 | | Subjects took the test preparation in the first cycle, and took the reference preparation in the second and third cycles; Subjects took the reference preparation in the first cycle, the test preparation in the second cycle, and the reference preparation in the third cycle; Subjects took the reference preparation in the first and second cycles, and took the test preparation in the third cycle; In the postprandial state, the subjects took the test preparation in the first cycle and took the reference preparation in the second and third cycles; In the postprandial state, subjects took the reference preparation in the first cycle, the test preparation in the second cycle, and the reference preparation in the third cycle; In the postprandial state, subjects took the reference preparation in the first and second cycles, and took the test preparation in the third cycle | Huzhou Central Hospital, Zhejiang; Zhejiang Jianfeng Pharmaceutical Co., Ltd, Zhejiang Jianfeng Pharmaceutical Co., Ltd | essential hypertension | | | | |
ChiCTR2200062994: A randomized, open-label, two-sequence, two-agent, four-cycle, fully replicated crossover bioequivalence trial of a single oral dose of valsartan and hydrochlorothiazide tablets in healthy subjects |
|
|
| Not yet recruiting | 1 | 112 | | R-T-R-T ;R-T-R-T ;T-R-T-R ;T-R-T-R | Huzhou Central Hospital; Zhejiang Ingle Pharmaceutical Co., Ltd., Zhejiang Ingle Pharmaceutical Co., Ltd. | Hypertension in all stages | | | | |
NCT05681273: Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects. |
|
|
| Completed | 1 | 48 | RoW | Chiglitazar, Empagliflozin, Atorvastatin, Valsartan | Chipscreen Biosciences, Ltd. | T2DM | 03/23 | 03/23 | | |
NCT06248112: Sacubitril 97 mg and Valsartan 103 mg Film-coated Tablets Relative to Entresto 97 mg/103 mg Film-coated Tablets |
|
|
| Not yet recruiting | 1 | 40 | NA | Sacubitril and Valsartan-Test product, Sacubitril and Valsartan-Reference product | Bio-innova Co., Ltd | Healthy Subjects | 06/24 | 07/24 | | |
ChiCTR2300073616: Efficacy and safety of azilsartan in mild-to-moderate non-dipper essential hypertension: a randomized controlled open-label study |
|
|
| Recruiting | 1 | 178 | | azilsartan treatment; Valsartan treatment | Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, Qilu hospital | hypertension | | | | |
| Not yet recruiting | 1 | 76 | | test preparation- reference preparation- test preparation- reference preparation; reference preparation- test preparation- reference preparation- test preparation; test preparation- reference preparation- test preparation- reference preparation; reference preparation- test preparation- reference preparation- test preparation | Shulan (Hangzhou) Hospital; Yusongyuan Pharmaceutical Co., LTD, Yusongyuan Pharmaceutical Co., LTD | Chronic heart failure, high blood pressure | | | | |
| Recruiting | 1 | 420 | US | Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Allegra, Zantac, Angiotensin-II, Valsartan, Diovan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, Regitine, BQ-123, MitoQ, BH4 | Russell Richardson | Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension | 08/25 | 08/25 | | |
ChiCTR-IOR-16008847: Clinical Study of Huangqi Decoction/Astragalus Decoction in the Treatment of 'Qi-Yin Vital Essence Deficiency' Type DKD III Patients |
|
|
| Recruiting | N/A | 240 | | astragalus decoction, valsartan ;valrtan，placebo | Shanghai Putuo District Central Hospital; Shanghai Putuo District Central Hospital, Shanghai Health Family Planning Committee “Three -Year Action Plan of Chinese Medicine Pharmaceutical Development in Shanghai” Project Number:ZY3-CCCX-3-3003 | Diabetic nephropathy | | | | |
ChiCTR-IOR-16010174: Clinical Study on Treatment of spleen and kidney Yang deficiency type of IgA nephropathy proteinuria with 'Huangqi guizhi wuwu' decoction |
|
|
| Recruiting | N/A | 100 | | Basic treatment+Valsartan Capsules treatment ;Basic treatment+Huangqi guizhi wuwu decoction treatment | Shuguang Hospital affliliated to Shanghai Univesrity of TCM; Shuguang Hospital affliliated with shanghai Univesrity of TCM, The municipal fiscal funds and unit self-raised funds | IgA nephropathy | | | | |
ChiCTR-INR-17011060: Shendi Granules on PBMC apoptosis and MCP-1, TGF- beta 1 in chronic glomerulonephritis patients with spleen and kidney deficiency syndrome |
|
|
| Not yet recruiting | N/A | 60 | | conventional therapy+Shendi Granules ;conventional therapy+Valsartan | the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine; Level of the institution：, Self financing | Chronic glomerulonephritis | | | | |
| Recruiting | N/A | 72 | | Valsartan and Amlodipine Tablets (I) ;缬沙坦氨氯地平片（I） | West China Hospital, Sichuan University; West China Hospital, Sichuan University, independently | 高血压 | | | | |
ChiCTR-INR-17012070: Yongquan acupoint Shenque moxibustion curative effect of traditional Chinese medicine in the treatment of membranous nephropathy |
|
|
| Not yet recruiting | N/A | 150 | | Yongquan Shenque paste of Chinese medicine with mild moxibustion ;Valsartan Tablets | Shijiazhuang Nephropathy Hospital; Shijiazhuang Nephropathy Hospital, raise independently | Membranous nephropathy | | | | |
ChiCTR-OOD-17013741: Effect of fully blocking type 1 angiotensin receptor on blood pressure, cardiac structure, cardiac function and cognitive function in postmenopausal hypertensive women |
|
|
| Not yet recruiting | N/A | 98 | | Different doses of valsartan | Lanzhou University Second Hospital; Lanzhou University Second Hospital, Scientific research project of Gansu health industry | hypertension | | | | |
ChiCTR2000041383: Single-center, randomized open clinical trial of the clinical efficacy and safety of Sakubatravalsartan Sodium Tablets (Noxinto) 100mg, bid in the early application of PCI after acute myocardial infarction |
|
|
| Recruiting | N/A | 70 | | Valsartan ;Sacurbacter Valsartan | Department of Cardiology, Tangdu Hospital; Tangdu Hospital, Fourth Military Medical University, none | Acute myocardial infarction | | | | |
ChiCTR2000030912: Clinical observation of Dachaihu decoction in the treatment of Irascibility hyperactivity syndrome(overabundant liver-fire syndrom) of hypertension |
|
|
| Not yet recruiting | N/A | 194 | | Dachaihu soup granule formula ;Valsartan capsule | Affiliated Hospital of Shandong University of TCM; Affiliated Hospital of Shandong University of TCM, Shandong development and reform commission | Essential hypertension | | | | |
ChiCTR2000031060: The Network Pharmacology and Mechanism Analysis of Xianxiong Chengqi Decoction in Treating Hypertension with Phlegm and Blood Stasis Syndrome |
|
|
| Not yet recruiting | N/A | 194 | | granules of xianxiongchengqi decoction ;Valsartan capsule | Affiliated Hospital of Shandong University of TCM; Affiliated Hospital of Shandong University of TCM, Shandong development and reform commission | Essential hypertension | | | | |
ChiCTR2000031103: Clinical study and Mechanism of Huanglian jiedu decoction in the treatment of Hypertension with hyperactivity of liver fire Syndrome based on Network Pharmacology |
|
|
| Not yet recruiting | N/A | 194 | | granules of Huanglianjiedu decoction ;Valsartan capsule | Affiliated Hospital of Shandong University of TCM; Affiliated Hospital of Shandong University of TCM, Shandong development and reform commission | Essential hypertension | | | | |
ChiCTR2000031117: A randomized controlled trial for the clinical effect of Wu-Mei-Wan Decoction in the treatment of primary hypertension with upper heat and lower cold syndrome |
|
|
| Not yet recruiting | N/A | 194 | | granules of ;Valsartan capsule | Affiliated Hospital of Shandong University of TCM; Affiliated Hospital of Shandong University of TCM, Shandong development and reform commission | Essential hypertension | | | | |
ChiCTR2000031157: Mechanism and Clinical research of Zhenganxifeng dispensing granule decoction for treatment of hypertension with Yin Deficiency and Yang Hyperactivity Syndrome based on network pharmacology |
|
|
| Not yet recruiting | N/A | 194 | | Zhenganxifeng dispensing granule decoction ;Valsartan capsule | Affiliated Hospital of Shandong University of TCM; Affiliated Hospital of Shandong University of TCM, Shandong development and reform commission | Essential hypertension | | | | |
ChiCTR2000033890: Clinical efficacy evaluation of Qingda Granule in the treatment of hypertension (grade 1, low to medium-risk) patients: a multicenter, randomized, double-blind, double-simulated, parallel-controlled, non-inferiority clinical study |
|
|
| Recruiting | N/A | 552 | | Qingda granules + Valsartan capsule simulation agent: Qingda granules 1 bag/time, 2 times/day; Valsartan capsule analog, 1 capsule/day. ;Valsartan capsule + Qingda granules simulation agent: Qingda granules simulation agent 1 bag/time, 2 times/day; Valsartan capsule, 1 capsule/day. | Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences; Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences, The management | hypertension | | | | |
ChiCTR1800020241: Investigation for Risk Factors of Membrane Nephropathy in Guangxi and Study for Intervention of Vitamin D |
|
|
| Recruiting | N/A | 120 | | Active Vitamin D 0.5ug/day ;Valsartan capsule 160mg/day ;Active vitamin D 0.5ug / day + valsartan capsule 160mg / day | The People's Hospital of Guangxi Zhuang Autonomous Region; The People's Hospital of Guangxi Zhuang Autonomous Region, Science and Technology Bureau of Qingxiu District, Nanning City, Guangxi Zhuang Autonomous Region | Idiopathic membranous nephropathy | | | | |
ChiCTR2000039700: A single center randomized controlled clinical study on the treatment of Children with Purpura nephritis with Huai-Qi-Huang Granules |
|
|
| Recruiting | N/A | 10 | | Huaiqihuang ;valsartan | Children's Hospital, Zhejiang University School of Medicine; Children's Hospital, Zhejiang University School of Medicine, Chen Xiaoping Foundation for the Development of Science and Technology of Hubei Province | Children with purpura nephritis | | | | |
| Not yet recruiting | N/A | 45 | | Tangshenkang + ACEI class of drugs (benazepril) ;ACEI (benazepril) + ARB drug (valsartan) ;ACEI class of drugs(benazepri) | Yangzhou University Medicine college; Yangzhou University Medicine college, Jiangsu Provincial Traditional Chinese Medicine Bureau Science and Technology Project Plan | Diabetic nephropathy | | | | |
ChiCTR1900026018: Wenshen-Huatan-Quyu particle combined with valsartan for benign hypertensive nephrosclerosis: a randomized controlled trial |
|
|
| Not yet recruiting | N/A | 70 | | Wenshen-Huatan-Quyu particle plus valsartan ;Wenshen-Huatan-Quyu placebo plus valsartan | Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine; Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai Science and Technology Commission Guiding Project (No. 19401943700) | Chironic kidney disease | | | | |
ChiCTR1800015179: Clinical effect of Mudan granule on diabetic microvascular complication. |
|
|
| Not yet recruiting | N/A | 1140 | | Diovan ;Mudan granule ;Diovan and Mudan granule ;Diovan ;Diovan ;Diovan and Mudan granule | Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University; Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, None | diabetic microvascular complication | | | | |
ARNI-HD, ChiCTR2100042186: Application of sacubarb / valsartan in maintenance hemodialysis patients with preserved ejection fraction heart failure: a single arm study |
|
|
| Recruiting | N/A | 200 | | sacubarb/valsartan taken | Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College Hospital, raise the fund independently | End Stage Renal Disease, Heart Failure | | | | |
AWARD-HF2, ChiCTR1900028191: Withdrawal of Neprilysin Inhibition for heart failure in ARNI responders with recovered ischemic cardiomyopathy |
|
|
| Not yet recruiting | N/A | 50 | | continous administration ARNI ;stop ARNI, only taking Valsartan | Changzhou 2nd Hospital; Nanjing First Hospital, no sponsor | ischemic heart disease | | | | |
ChiCTR2200064406: Effect of sarcubitril valsartan in antihypertension and improvement of prognosis of cardiovascular diseases in patients on hemodialysis |
|
|
| Recruiting | N/A | 181 | | sarcubitril valsartan | Department of Nephrology Peking University First Hospital; Peking University First Hospital, Suzhou Industrial Park Xinxin Cardiovascular Health Foundation | N/A | | | | |
ChiCTR2100053690: Clinical efficacy of combining Huaiqihuang Granules with ARB in the treatment of chronic glomerulonephritis (Qi and Yin deficiency type)-a prospective randomized controlled study |
|
|
| Recruiting | N/A | 36 | | Valsartan Tablets combined with Huaiqihuang Granules ;Valsartan Tablets | the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine; the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Hubei Chen Xiaoping Science and Technology Development Foundation CXPJJH21002-202106 | Chronic glomerulonephritis | | | | |
ChiCTR2000035168: Evaluation The Influence of Duration after Sacubatril/valsartan Initiation on Short-term and Long-term Prognosis in Patients with Acute Heart Failure |
|
|
| Not yet recruiting | N/A | 800 | | ACEI/ARB ;Sacubatril/valsartan | Zhongshan Hospital Fudan University; Zhongshan Hospital Fudan University, Other | acute heart failure | | | | |
NCT06344247: Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease |
|
|
| Recruiting | N/A | 48 | RoW | RAS inhibitors：Losartan®️/Valsartan®️, dapagliflozin：Forxiga®️, simagliptin：Forxiga®️, Semaglutide®️ | RenJi Hospital | Obesity, Chronic Kidney Diseases | 09/25 | 12/25 | | |
| Not yet recruiting | N/A | 63 | | Chuanhuang No.1 prescription+ Valsartan ;valsartan | Shanghai Dong Fang Hospital; Shanghai Dong Fang Hospital, self-raised | Primary IgA nephropathy | | | | |
ChiCTR2200056016: Evidence-based evaluation of Qidan Tangshen granule in the treatment of early diabetic kidney diease |
|
|
| Recruiting | N/A | 200 | | Qidan Tangshen granule, Valsartan simulator ;Qidan Tangshen granule simulator, Valsartan | LongHua Hospital Shanghai University of Traditional Chinese Medicine; LongHua Hospital Shanghai University of Traditional Chinese Medicine, Science & Technology Department of Shanghai | Type 2 diabetic nephropathy | | | | |
ChiCTR2200062663: A clinical study of traditional Chinese medicine combined with western medicine in treatment of primary IgA nephropathy (IgAN) in CKD stage 3 |
|
|
| Not yet recruiting | N/A | 63 | | oral valsartan ;Valsartan + Chuanhuang 1 prescription | Shanghai East Hospital (East Hospital Affiliated to Tongji University); Shanghai East Hospital (East Hospital Affiliated to Tongji University), Shanghai East Hospital (East Hospital Affiliated to Tongji University) | IgA nephropathy | | | | |
ChiCTR2300078508: To evaluate the clinical randomized controlled study of warming acupuncture combined with Western medicine in the treatment of chronic heart failure with Yang deficiency and blood stasis and observe its effect on inflammatory factors |
|
|
| Recruiting | N/A | 68 | | 1.The patients are given warming needles.The point selection: bilateral Neiguan point, Xinshu point, Jueyin point, Shenshu point, Neiguan point, Yin Cleft point, Zusanli, Sanyin Jiao, Blood Sea. The treatment was performed 3 times a week and total for 4 weeks.2. Sacubactril valsartan tablets; Metoprolo tattrate tablets; Empagliflozin tablets; spironolactone tablet; Sacubactril valsartan tablets; Metoprolo tattrate tablets; Empagliflozin tablets; spironolactone tablet | Jing'an District Hospital of Traditional Chinese Medicine (TCM); Jing'an District Hospital of Traditional Chinese Medicine (TCM), Shanghai 200072, China, self-finance | chronic heart failure | | | | |
NCT05271448: Continuing or Discontinuing ACE/ARBs in Patients With Chronic Kidney Disease Undergoing Coronary Angiography |
|
|
| Recruiting | N/A | 600 | RoW | Continue ACEI or ARBs ( Enalapril , Ramipril , Valsartan , Candesartan, Losartan ), Continue ACEI or ARBs, Hold ACEI or ARBs | An-Najah National University | Contrast-induced Nephropathy, Chronic Kidney Diseases, Ischemic Heart Disease | 06/24 | 08/24 | | |
ChiCTR2300071967: Observation on the clinical efficacy of Shen Ge San combined with enhanced external counterpulsation in improving chronic heart failure |
|
|
| Recruiting | N/A | 108 | | On the basis of standard Western medicine treatment (valsartan 40/80mg qd po, spironolactone 20mg qd/bid po, metoprolol 12.5mg/25mg qd/bid po;) combined with EECP treatment, take Shen Ge San twice a day, 3g each time; ;On the basis of standard Western medicine treatment (valsartan 40/80mg qd po, spironolactone 20mg qd/bid po, metoprolol 12.5mg/25mg qd/bid po;) combined with EECP, take a placebo twice a day, 3g each time; | Shanghai Jing'an District Shibei Hospital ; Shanghai Jing'an District Shibei Hospital, Shanghai Municipal Health Commission | chronic heart failure | | | | |
